The ATS 2026 International Conference offers a robust scientific program highlighting cutting-edge advancements in pulmonary, critical care, and sleep medicine. This includes several Postgraduate Courses, Scientific Symposia, and Meet the Expert sessions addressing new developments and considerations in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), as listed below. A curated list of clinical and scientific sessions related to these topics is also available on the ATS365 platform. For more information on these and other sessions to be presented May 15–20 in Orlando, Fla., visit the online Advance Program.
- A106 YOU’VE GOT A FRIEND IN ME: BASIC, GENETIC, AND OMICS RESEARCH TO ADVANCE CHILDREN’S RESPIRATORY HEALTH
- A109 FROM CELLS TO CIRCULATION: DETERMINANTS OF PULMONARY FIBROSIS SEVERITY AND PROGRESSION
- A10 IS IT SARCOIDOSIS? – I DON’T KNOW
- A110 CLOSING THE GAP: ADVANCES IN PULMONARY FIBROSIS
- A12 DO NO HARM, UNLESS THE AI SAYS OTHERWISE – AI ETHICS, A PRO/CON
- A15 CATCHING FIBROSIS IN THE ACT: ILD SCREENING AND ILA
- A20 A PICTURE PAINTS A THOUSAND WORDS: IMAGING PULMONARY STRUCTURE AND FUNCTION
- A22 IMMUNOLOGICAL INSIGHTS IN ILD AND TRANSPLANT OUTCOMES
- A24 ALGORITHMS IN ACTION: APPLICATIONS OF ARTIFICIAL INTELLIGENCE ACROSS PULMONARY DISEASES
- A29 PHYSICAL ACTIVITY, EXERCISE AND PULMONARY REHABILITATION FROM AROUND THE GLOBE
- A2 VISUALIZING THE TARGET: IMAGE-BASED MULTIMODAL PROFILING OF MICRO AND MACROENVIRONMENT IN LUNG DISEASE
- A35 DECODING PARENCHYMAL LUNG DISEASE: INTERSTITIAL AND VASCULITIC INSIGHTS
- A37 UNDER PRESSURE: CARDIOPULMONARY DISEASES, DIAGNOSES, AND MANAGEMENT
- A39 PHARMACOLOGIC THERAPIES AND TRIALS IN ILD
- A3 FELLOWS CASE CONFERENCE
- A41 CASE REPORTS IN ONCOLOGIC THERAPY–RELATED PULMONARY TOXICITY
- A42 FROM VAPOR RUB TO COCAINE: CASE REPORTS IN INHALATIONAL AND SUBSTANCE INDUCED LUNG DISEASE
- A43 CASE REPORTS IN CHALLENGING ILD DIAGNOSIS AND MANAGEMENT
- A55 OPTIMIZING VENTILATORY SUPPORT ACROSS THE SPECTRUM OF ACUTE RESPIRATORY FAILURE
- A58 LARGE-SCALE ANALYSES SHAPING THE FUTURE OF RESPIRATORY MEDICINE
- A72 CASE REPORTS FROM THE PULMONARY REHABILITATION ASSEMBLY
- A74 SENESCENCE, TISSUE MECHANICS, AND FIBRO-INFLAMMATORY CROSSTALK IN LUNG FIBROSIS
- A78 CASE REPORTS IN LUNG STRUCTURE AND FUNCTION I
- A81 PEDIATRIC YEAR IN REVIEW: THE MAGIC KINGDOM OF PEDIATRIC PULMONARY
- A83 GREAT CASES: CLINICAL, RADIOLOGIC, AND PATHOLOGIC CORRELATIONS BY MASTER CLINICIANS
- A87 YOU BREATHE WHAT YOU EAT – EFFECTS OF NUTRITION ON LUNG HEALTH AND DISEASE
- A89 REDEFINING CARE: STRATEGIES FOR EFFECTIVE PATIENT-CENTERED MANAGEMENT ACROSS THE CONTINUUM IN SERIOUS RESPIRATORY ILLNESS
- A8 THE WOUNDED LUNG: CELLULAR STRESS, INFLAMMATION AND CARCINOGENESIS
- A93 THE INTERSECTION OF IMMUNITY AND FIBROSIS: EXPOSURES AND MECHANISTIC OUTCOMES IN INTERSTITIAL LUNG DISEASE
- A94 CARE WITHOUT BORDERS: PULMONARY HEALTH IN COMMUNITIES AROUND THE WORLD
- A95 READING BETWEEN THE PIXELS: IMAGING, DIAGNOSIS, AND OUTCOMES IN ILD
- B101 DECODING DISEASE: BIOMARKERS, PHENOTYPES, AND PRECISION MEDICINE
- B105 HAKUNA MATATA: STRESS-FREE, NOVEL APPROACHES TO PREDICT, DIAGNOSE, AND MANAGE PEDIATRIC PULMONARY DISEASES
- B108 IMPROVING FUNCTION, STRENGTH AND OUTCOMES THROUGH PULMONARY REHABILITATION
- B110 THE NEW FRONTIER IS HERE: AI IN PULMONARY MEDICINE
- B17 BEST IN PEDIATRICS: BIBBIDI-BOBBIDI-BREATH!
- B19 EMERGING THERAPEUTIC STRATEGIES FOR FIBROTIC LUNG DISEASE
- B23 AI AND QUANTITATIVE IMAGING FOR DIAGNOSIS AND OUTCOME PREDICTION IN ILD
- B27 BREATH OF FRESH AIR: JOURNEY FROM DIAGNOSIS TO RECOVERY IN PULMONARY AND CRITICAL CARE
- B2 ACHIEVING EQUITY IN PULMONARY FIBROSIS: FROM PATIENT VOICES TO PRACTICE INNOVATION
- B35 RARE AIR: JUMPING INTO UNIQUE CASES OF INTERSTITIAL LUNG DISEASE AND VASCULITIS
- B38 TRAINING THAT TRANSLATES: EDUCATION AND QUALITY IMPROVEMENT IN PULMONARY AND CRITICAL CARE
- B39 BREATH AND BURDEN: DIFFUSE LUNG DISEASES AND DAILY LIFE
- B40 BSHSR LATE-BREAKING ABSTRACTS
- B41 FROM CHATGPT TO CRYOBIOPSY: MODERN TOOLS AND INSIGHTS IN ILD
- B42 NEW INSIGHTS IN SARCOIDOSIS AND RARE LUNG DISEASES
- B43 CASE REPORTS IN PULMONARY MANIFESTATIONS OF AUTOIMMUNE DISEASE
- B58 ASSESSING LUNG HEALTH IN THE REAL WORLD
- B59 RECENT INNOVATIONS IN PULMONARY AND CRITICAL CARE DISEASE MANAGEMENT
- B5 NOVEL INSIGHTS INTO THE COMPLEMENT INFLUENCE ON LUNG MICROENVIRONMENT IN ACUTE AND CHRONIC DISEASE
- B6 OMICS TO ACTION: REDESIGNING TRIALS AND CARE IN RESPIRATORY MEDICINE
- B74 PULMONARY REHABILITATION ACROSS DIFFERENT SETTINGS AND DISEASES
- B77 FROM TARGET DISCOVERY TO CLINICAL TRANSLATION IN PULMONARY FIBROSIS
- B79 PULMONARY FIBROSIS: BENCH TO BEDSIDE
- B84 CONTROVERSIES IN INTERSTITIAL LUNG DISEASE: A PRO-CON
- B85 BEYOND -OMICS: CONNECTING MOLECULAR BIOLOGY TO CELL PATHOPHYSIOLOGY USING SPATIO-TEMPORAL MULTI-MODAL IMAGING
- B88 REWRITING THE CODE: PRECISION DELIVERY VECTORS AND GENE THERAPY FOR PULMONARY VASCULAR DISEASES
- B89 FROM BENCH TO THRIVING: RECENT BREAKTHROUGHS IN CHILDHOOD INTERSTITIAL LUNG DISEASES
- B8 PULMONARY REHABILITATION IN NON-COPD PATIENTS: UPDATES ON THE EVIDENCE, CLINICAL INDICATIONS AND PHYSIOLOGY
- B92 ESCALATING USE, EMERGING SCIENCE: VAPE/SMOKE INDUCED LUNG DISEASE
- B93 LIVING LANDSCAPES: HOW LUNG MICROENVIRONMENTS ORCHESTRATE HOST RESPONSE DURING LUNG INFECTIONS
- B95 FIBROSIS, COUGH, AND INFLAMMATION: TREATMENT STRATEGIES IN ILD
- B9 PULMONARY FUNCTION IN CHILDHOOD RESPIRATORY DISEASE: EVIDENCE, SOCIAL DETERMINANTS, AND TRAJECTORIES
- C102 FROM KNOWING TO DOING: EDUCATING AND IMPLEMENTING EVIDENCE-BASED PULMONARY CARE
- C103 THE NEXT FRONTIER OF THERAPY IN PULMONARY FIBROSIS
- C104 THERAPEUTICS, BIOMARKERS, AND REAL-WORLD EVIDENCE IN ILD
- C108 STRUCTURE MEETS FUNCTION: MEASUREMENTS OF THE LUNG
- C10 PULMONARY REHABILITATION AROUND THE WORLD: LEARNING FROM THE FRONTLINES
- C13 WHAT TO EXPECT WHEN YOUR PATIENT IS EXPECTING: PREGNANCY IN PCCM
- C15 MICROBIAL MAESTROS: TOWARDS MECHANISMS OF MICROBIOME INFLUENCE IN LUNG DISEASE
- C16 MARKETS AND MANDATES: HEALTH POLICY AND PULMONARY OUTCOMES
- C20 THE NEXT TOP MODEL: NOVEL LUNG MODELS FOR INVESTIGATING PULMONARY HEALTH AND DISEASE
- C29 SENESCENCE, METABOLISM, AND CELL FATE IN LUNG REPAIR AND FIBROSIS
- C2 IMMUNE ACTIVATION AND FIBROSIS WITHIN THE PULMONARY VASCULAR MICROENVIRONMENT
- C38 LIVING WITH LUNG DISEASE WORLDWIDE: CARE, BURDEN, AND ADAPTATION
- C39 IF IT CAN BE MEASURED: BIOMARKERS, IMAGING, AND PHYSIOLOGY IN ILD
- C3 PEDIATRIC CLINICAL CHEST ROUNDS: MICKEY’S MYSTERY CLUB
- C41 WHEN THE LUNGS BLEED: CASE REPORTS IN VASCULITIS, LUPUS, AND DIFFUSE ALVEOLAR HEMORRHAGE
- C42 WHEN THERAPY TURNS TOXIC: CASE REPORTS IN DRUG-INDUCED LUNG DISEASE
- C48 NON-INFECTIOUS ACUTE LUNG INJURY AND ARDS
- C59 CASE REPORTS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH
- C62 CHILDHOOD INTERSTITIAL AND RARE LUNG DISEASES: PETER PAN’S FLIGHT
- C6 EVOLVING FROM SUBJECTIVE DIAGNOSTIC CATEGORIES TO MOLECULAR ENDOTYPES IN ILD
- C73 SEEING IS BELIEVING: NEW DEVELOPMENTS IN LUNG IMAGING
- C7 NEW APPROACHES TO THE PATIENT WITH CHRONIC PRODUCTIVE COUGH
- C82 LUNG FIBROSIS ACROSS THE LIFESPAN: EMERGING OPPORTUNITIES FOR INTERVENTION
- C85 ATS GUIDELINES AND CLINICAL STATEMENTS: CONTROVERSIES IN RESPIRATORY FAILURE AND ILA/ILD
- C91 PRIMARY PALLIATIVE CARE IN PULMONARY-CRITICAL CARE MEDICINE: A ‘PALLIPULM’ FRAMEWORK FOR EDUCATION, PRACTICE, AND POLICY
- C97 NOVEL APPROACHES AND UNDERSTANDING TO SKELETAL MUSCLE, REHABILITATION AND ACUTE RECOVERY
- D102 METHODS, MEASUREMENT, AND MEANING: CROSS-CUTTING CHALLENGES IN PULMONARY CARE
- D103 CASE REPORTS IN ILD POTPOURRI
- D109 NOVEL INSIGHTS INTO PULMONARY VASCULAR DISEASES
- D12 INEQUITIES BY DESIGN: SOCIAL AND STRUCTURAL DRIVERS OF PULMONARY HEALTH
- D19 THE NEXT GENERATION: NOVEL TARGETS AND THERAPIES FOR CHRONIC LUNG DISEASE
- D22 FROM SCREENING TO SURVIVAL: UNEQUAL PATHS IN PULMONARY CARE
- D23 MOLECULAR PROFILING TO PATIENT-REPORTED OUTCOMES — INTEGRATING PHENOTYPES AND REAL-WORLD DATA IN ILD
- D26 THE UNINTENDED CONSEQUENCES: ENVIRONMENTAL IMPACTS OF AIR POLLUTION, CLIMATE CHANGE, AND MODERN LUNG DISEASE TREATMENT
- D27 MIRROR, MIRROR ON THE WALL: WHO HAS THE BEST PEDIATRIC PULMONARY CASE OF ALL?
- D29 NEXT-GENERATION ANTI-FIBROTIC THERAPIES: TARGETS, TECHNOLOGIES, AND TRANSLATION
- D2 A TALE OF TWO TRANSPLANTS: THE CONVERGENT PATHS OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION AND PULMONARY GRAFT VERSUS HOST DISEASE
- D6 MEET THE BOS: PHENOTYPES AND PATHWAYS IN BRONCHIOLITIS OBLITERANS SYNDROME
- D7 ENDOTHELIAL HETEROGENEITY IN THE LUNG MICROENVIRONMENT: AGE AND DISEASE PERSPECTIVES
- D86 LOCATION, LOCATION, LOCATION: INTERCELLULAR COMMUNICATION DRIVING LUNG DISEASE
- D92 NEW THERAPEUTICS, INTERVENTIONS, AND MONITORING IN CHRONIC RESPIRATORY DISEASE
- D95 GOOD INTENTIONS, BAD OUTCOMES: HOW LUNGS BECOME FIBROTIC
- MD13 RED JOURNAL IN ACTION 2: LUNG REPAIR MODELS AND MECHANISMS
- MD15 WHEN THE FUNDING STOPS: NAVIGATING RESEARCH IN A SHIFTING LANDSCAPE
- MD16 USING NASA SATELLITE DATA TO GUIDE NOVEL AIR QUALITY APPLICATIONS
- MD17 FUNDAMENTALS OF HIGH-RESOLUTION CT OF THE LUNGS
- MD19 PULMONARY UPDATE FROM THE US FOOD AND DRUG ADMINISTRATION
- MD1 RED JOURNAL IN ACTION 1: EARLY CAREER LUNG RESEARCH HIGHLIGHTS
- MD20 LEVERAGE HUMAN-BASED APPROACHES TO STUDY LUNG RESILIENCE AND DISEASE
- MD23 INTERROGATING INTERACTIONS BETWEEN IMMUNITY, MECHANICS, AND ORGAN SYSTEMS IN PULMONARY FIBROSIS
- MD24 LUNGMAP PHASE 3- NOVEL TECHNOLOGY, DATA SCIENCE, AND RESOURCES
- MD26 LUNG MAP PHASE 3- HIGH RESOLUTION MOLECULAR PROFILING OF LUNG DISEASES
- MD6 VHA LUNG PRECISION ONCOLOGY PROGRAM: KEY FINDINGS FROM SCREENING RESEARCH
- MTE10 USE OF BIOLOGIC THERAPIES IN THE TREATMENT OF INTERSTITIAL LUNG DISEASE
- MTE11 SELECTION AND MANAGEMENT OF “HIGH RISK” LUNG TRANSPLANT CANDIDATES
- MTE15 POTENTIAL AND PITFALLS OF AI FOR CLINICIANS AND EDUCATORS
- MTE22 UNRAVELING THE STORM: MANAGING ACUTE EXACERBATIONS OF INTERSTITIAL LUNG DISEASES
- MTE23 FROM SURVIVING TO THRIVING: POST-TRAUMATIC GROWTH FOR HEALTH PROFESSIONALS & TRAINEES IN HIGH-ACUITY SETTINGS
- MTE27 FROM FLATLINE TO FIRST DRAFT: A NARRATIVE RESUSCITATION WORKSHOP FOR BURNOUT RECOVERY
- MTE34 TO PNEUMONITIS AND BEYOND: A COMPREHENSIVE REVIEW OF DYSPNEA FROM IMMUNE CHECKPOINT INHIBITORS
- MTE35 FROM FEATHERS TO ANTIFIBROTICS: EXPOSURES, DIAGNOSIS, AND TREATMENT IN HYPERSENSITIVITY PNEUMONITIS
- MTE36 PH RELATED TO ILD: CURRENT EVIDENCE AND OUTSTANDING QUESTIONS
- MTE4 SMALL BUT MIGHTY-EVS IN LUNG HEALTH AND DISEASE
- PG13 INTERSTITIAL LUNG DISEASE: A PRACTICAL APPROACH TO DIAGNOSIS AND MANAGEMENT
- PG1A TAKE IT ALL IN!: COMPREHENSIVE REVIEW OF PEDIATRIC PULMONOLOGY AND PREPARATION FOR THE BOARDS
- PG1B TAKE IT ALL IN!: COMPREHENSIVE REVIEW OF PEDIATRIC PULMONOLOGY AND PREPARATION FOR THE BOARDS
- PG21 TRANSLATIONAL WINDOWS INTO THE LUNG MICROENVIRONMENT: ADVANCES WITH PRECISION-CUT LUNG SLICES
- PG2 ULTRASOUND UNLOCKED: ADVANCING ULTRASOUND PRACTICE AND INSTRUCTION
- PG3 BRONCH DAY 2026: A COMPREHENSIVE, HANDS-ON GUIDE TO BASIC BRONCHOSCOPY, EBUS, AND GUIDED BRONCHOSCOPY
- PG6 BEST PRACTICES IN PULMONARY FUNCTION TESTING
- Respiratory Society of Americas Session: Interstitial Lung Disease Across the Americas: Adult and Pediatric Perspectives
Don’t Miss the ATS 2026 International Conference
Register today for the ATS 2026 International Conference to experience this year’s premier respiratory health conference, May 15-20 in Orlando. Join your colleagues to learn about the latest developments in pulmonary, critical care, and sleep medicine.
Not an ATS member? Join today and save on your conference registration!